loading
前日終値:
$19.14
開ける:
$19.15
24時間の取引高:
350.56K
Relative Volume:
0.59
時価総額:
$1.16B
収益:
$688.00K
当期純損益:
$-170.19M
株価収益率:
-6.4865
EPS:
-2.96
ネットキャッシュフロー:
$-154.68M
1週間 パフォーマンス:
+15.00%
1か月 パフォーマンス:
+22.49%
6か月 パフォーマンス:
+56.87%
1年 パフォーマンス:
-33.21%
1日の値動き範囲:
Value
$18.12
$19.71
1週間の範囲:
Value
$16.00
$21.51
52週間の値動き範囲:
Value
$10.91
$40.26

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
名前
Spyre Therapeutics Inc
Name
セクター
Healthcare (1146)
Name
電話
(617) 651-5940
Name
住所
221 CRESCENT STREET, WALTHAM
Name
職員
65
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
SYRE's Discussions on Twitter

SYRE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SYRE
Spyre Therapeutics Inc
19.18 1.16B 688.00K -170.19M -154.68M -2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
408.31 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
472.79 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.47 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
801.26 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
331.58 35.16B 4.56B -176.77M 225.30M -1.7177

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-09-26 開始されました Deutsche Bank Buy
2025-04-08 開始されました Leerink Partners Outperform
2025-03-18 開始されました Wolfe Research Outperform
2024-09-04 開始されました Wedbush Outperform
2024-07-16 開始されました Evercore ISI Outperform
2024-05-02 開始されました Robert W. Baird Outperform
2024-03-01 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-20 開始されました BTIG Research Buy
2023-12-11 開始されました Guggenheim Buy
2023-12-11 開始されました Jefferies Buy
2020-05-04 開始されました Piper Sandler Overweight
2019-03-21 開始されました JP Morgan Overweight
2018-09-04 ダウングレード Wells Fargo Outperform → Market Perform
2018-04-24 開始されました Evercore ISI Outperform
2018-03-14 繰り返されました Needham Buy
すべてを表示

Spyre Therapeutics Inc (SYRE) 最新ニュース

pulisher
11:29 AM

Using Python tools to backtest Spyre Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - newser.com

11:29 AM
pulisher
11:12 AM

Will Spyre Therapeutics Inc. stock pay special dividendsNew Guidance & Accurate Buy Signal Notifications - newser.com

11:12 AM
pulisher
09:53 AM

Can Spyre Therapeutics Inc. stock sustain free cash flow growth2025 Major Catalysts & Entry Point Confirmation Signals - newser.com

09:53 AM
pulisher
08:30 AM

Why Spyre Therapeutics Inc. stock is a value investor pickQuarterly Trade Review & High Win Rate Trade Tips - newser.com

08:30 AM
pulisher
01:54 AM

What sentiment indicators say about Spyre Therapeutics Inc. stockJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com

01:54 AM
pulisher
01:51 AM

Best data tools to analyze Spyre Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com

01:51 AM
pulisher
Oct 12, 2025

Will Spyre Therapeutics Inc. stock recover faster than peersMarket Trend Summary & Daily Profit Maximizing Trade Tips - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Here's Why - MarketBeat

Oct 11, 2025
pulisher
Oct 09, 2025

Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 08, 2025

Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat

Oct 08, 2025
pulisher
Oct 06, 2025

Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Published on: 2025-10-06 01:19:10 - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus

Oct 05, 2025
pulisher
Oct 05, 2025

Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative

Oct 05, 2025
pulisher
Oct 05, 2025

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times

Oct 05, 2025
pulisher
Oct 05, 2025

6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan

Oct 05, 2025
pulisher
Oct 05, 2025

Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Spyre Therapeutics Inc. (3920) stock inflation resilientMarket Risk Analysis & AI Driven Price Predictions - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times

Oct 03, 2025
pulisher
Oct 03, 2025

42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees - Stock Titan

Oct 03, 2025
pulisher
Oct 03, 2025

What Fibonacci levels say about Spyre Therapeutics Inc. reboundJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

What candlestick patterns are forming on Spyre Therapeutics Inc.Trend Reversal & Weekly High Conviction Ideas - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Why millennials buy Spyre Therapeutics Inc. (3920) stockTrade Risk Report & Smart Swing Trading Techniques - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.29 Average PT from Brokerages - Defense World

Oct 03, 2025
pulisher
Oct 02, 2025

What analysts say about Spyre Therapeutics Inc 3920 stockStock Watchlist Updates & Low Risk Capital Growth - earlytimes.in

Oct 02, 2025
pulisher
Oct 01, 2025

What technical charts say about Spyre Therapeutics Inc. stockJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com

Oct 01, 2025
pulisher
Sep 30, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-29 23:52:21 - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-29 23:49:14 - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Published on: 2025-09-29 13:35:29 - newser.com

Sep 29, 2025

Spyre Therapeutics Inc (SYRE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Spyre Therapeutics Inc (SYRE) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Albers Jeffrey W.
Director
Nov 06 '24
Sale
36.76
6,700
246,313
27,360
Albers Jeffrey W.
Director
Oct 25 '24
Sale
36.43
300
10,929
34,060
$84.81
price up icon 1.12%
$22.95
price up icon 7.63%
$32.66
price up icon 2.66%
$102.39
price up icon 0.32%
$164.59
price up icon 1.50%
biotechnology ONC
$331.58
price up icon 3.40%
大文字化:     |  ボリューム (24 時間):